News
August 20 | 2010
SAVIRA PHARMACEUTICALS AWARDED GRANTS BY THE EUROPEAN COMMISSION AND THE AUSTRIAN RESEARCH PROMOTION AGENCY FOR THE DEVELOPMENT OF NOVEL INFLUENZA THERAPEUTICS
Savira receives funding as part of a consortium under the lead of the European Molecular Biology Laboratory (EMBL) that has been awarded a grant from the European Commission of EUR 6 million. Earlier this year, Savira received funding of kEUR 560 from the Austrian Research Promotion Agency (FFG) supporting its flu polymerase inhibitor development program.
July 29 | 2010
TOP MEDICINAL CHEMISTRY EXPERT HELMUT H. BUSCHMANN TO JOIN SAVIRA PHARMACEUTICALS AS CSO
Helmut H. Buschmann is a leading medicinal chemistry and senior management executive with 19 years of international experience in drug discovery research and drug development in the pharmaceutical and biotechnology industry with particular strengths in identifying, evaluating, and integrating pre-clinical projects and transfer to clinical development.
October 16 | 2009
SAVIRA AMONG THE MOST PROMISING VIENNA START-UP COMPANIES
Savira was awarded third place by the City of Vienna Future Award
September 23 | 2009
FOUNDATION OF SAVIRA PHARMACEUTICALS GMBH
Savira, an Austrian pharmaceutical company focusing on the development of novel anti-influenza drugs was recently established in Vienna and supported with seed financing of 1 Mio Euro by the AWS (Austria Wirtschaftsservice). Based on intellectual property from the co-founders, the European Molecular Biology Laboratory (EMBL) from Heidelberg, Germany and the biotech company onepharm from Vienna, Austria, Savira will manage a medicinal chemistry program aiming at the identification of lead candidates and the development of anti-influenza drugs.